Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England
Thomas FD Mason, Matt Whitston, Jack Hodgson, Ruth E Watkinson, Yiu-Shing Lau, Omnia Abdulrazeg, Matt Sutton
BMC MEDICINE | BMC | Published : 2021
BACKGROUND: The BNT162b2 mRNA vaccine has been shown to be effective at preventing serious COVID-19 events in clinical trials. There is less evidence on effectiveness in real-world settings, especially for older people. Here, we aimed to estimate vaccine effectiveness in the context of the rapid NHS mass-vaccination programme in England, exploiting age-based vaccination eligibility thresholds to minimise and correct for selection bias. METHODS: We studied 170,226 individuals between the ages of 80 and 83 years from community settings outside care homes who received one dose of BNT162b2 mRNA between the 15 and 20 December 2020 and were scheduled a second dose 21 days later. We matched these v..View full abstract
TM, JH, OA, and MW are funded by NHS England & NHS Improvement. RW is funded by The University of Manchester. MS is funded by the National Institute for Health Research (NIHR) Applied Research Collaboration for Greater Manchester. YL is funded by the NIHR Policy Research Programme via the Policy Research Unit in Health and Social Care Systems and Commissioning. MS is a NIHR Senior Investigator. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.